CCN5 Reduces Ligamentum Flavum Hypertrophy by Modulating the TGF-β Pathway

Sunghyeok Ye, Woo Keun Kwon, Taegeun Bae, Sunghyun Kim, Jang Bo Lee, Tai Hyoung Cho, Jung Yul Park, Kyoungmi Kim, Junho K. Hur, Junseok W. Hur

Research output: Contribution to journalArticle

Abstract

Ligamentum flavum hypertrophy (LFH) is the most important component of lumbar spinal canal stenosis. Although the pathophysiology of LFH has been extensively studied, no method has been proposed to prevent or treat it. Since the transforming growth factor-β (TGF-β) pathway is known to be critical in LFH pathology, we investigated whether LFH could be prevented by blocking or modulating the TGF-β mechanism. Human LF cells were used for the experiments. First, we created TGF-β receptor 1 (TGFBR1) knock out (KO) cells with CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 biotechnology and treated them with TGF-β1 to determine the effects of blocking the TGF-β pathway. Subsequently, we studied the effect of CCN5, which has recently been proposed to modulate the TGF-β pathway. To assess the predisposition toward fibrosis, α-smooth muscle actin (αSMA), fibronectin, collagen-1, collagen-3, and CCN2 were evaluated with quantitative real-time polymerase chain reaction, western blotting, and immunocytochemistry. The TGFBR1 KO LF cells were successfully constructed with high KO efficiency. In wild-type (WT) cells, treatment with TGF-β1 resulted in the overexpression of the messenger RNA (mRNA) of fibrosis-related factors. However, in KO cells, the responses to TGF-β1 stimulation were significantly lower. In addition, CCN5 and TGF-β1 co-treatment caused a notable reduction in mRNA expression levels compared with TGF-β1 stimulation only. The αSMA protein expression increased with TGF-β1 but decreased with CCN5 treatment. TGF-β1 induced LF cell transdifferentiation from fibroblasts to myofibroblasts. However, this cell transition dramatically decreased in the presence of CCN5. In conclusion, CCN5 could prevent LFH by modulating the TGF-β pathway.

Original languageEnglish
JournalJournal of Orthopaedic Research
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Ligamentum Flavum
Transforming Growth Factors
Hypertrophy
Smooth Muscle
Actins
Fibrosis
Collagen
Clustered Regularly Interspaced Short Palindromic Repeats
Cell Transdifferentiation
Spinal Stenosis
Messenger RNA
Spinal Canal
Myofibroblasts
Growth Factor Receptors
Muscle Proteins
Biotechnology
Fibronectins

Keywords

  • CCN5
  • CRISPR
  • ligamentum flavum
  • myofibroblast
  • TGF-β1

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine

Cite this

CCN5 Reduces Ligamentum Flavum Hypertrophy by Modulating the TGF-β Pathway. / Ye, Sunghyeok; Kwon, Woo Keun; Bae, Taegeun; Kim, Sunghyun; Lee, Jang Bo; Cho, Tai Hyoung; Park, Jung Yul; Kim, Kyoungmi; Hur, Junho K.; Hur, Junseok W.

In: Journal of Orthopaedic Research, 01.01.2019.

Research output: Contribution to journalArticle

@article{30dd6f374d224163bbfc985dbc894f69,
title = "CCN5 Reduces Ligamentum Flavum Hypertrophy by Modulating the TGF-β Pathway",
abstract = "Ligamentum flavum hypertrophy (LFH) is the most important component of lumbar spinal canal stenosis. Although the pathophysiology of LFH has been extensively studied, no method has been proposed to prevent or treat it. Since the transforming growth factor-β (TGF-β) pathway is known to be critical in LFH pathology, we investigated whether LFH could be prevented by blocking or modulating the TGF-β mechanism. Human LF cells were used for the experiments. First, we created TGF-β receptor 1 (TGFBR1) knock out (KO) cells with CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 biotechnology and treated them with TGF-β1 to determine the effects of blocking the TGF-β pathway. Subsequently, we studied the effect of CCN5, which has recently been proposed to modulate the TGF-β pathway. To assess the predisposition toward fibrosis, α-smooth muscle actin (αSMA), fibronectin, collagen-1, collagen-3, and CCN2 were evaluated with quantitative real-time polymerase chain reaction, western blotting, and immunocytochemistry. The TGFBR1 KO LF cells were successfully constructed with high KO efficiency. In wild-type (WT) cells, treatment with TGF-β1 resulted in the overexpression of the messenger RNA (mRNA) of fibrosis-related factors. However, in KO cells, the responses to TGF-β1 stimulation were significantly lower. In addition, CCN5 and TGF-β1 co-treatment caused a notable reduction in mRNA expression levels compared with TGF-β1 stimulation only. The αSMA protein expression increased with TGF-β1 but decreased with CCN5 treatment. TGF-β1 induced LF cell transdifferentiation from fibroblasts to myofibroblasts. However, this cell transition dramatically decreased in the presence of CCN5. In conclusion, CCN5 could prevent LFH by modulating the TGF-β pathway.",
keywords = "CCN5, CRISPR, ligamentum flavum, myofibroblast, TGF-β1",
author = "Sunghyeok Ye and Kwon, {Woo Keun} and Taegeun Bae and Sunghyun Kim and Lee, {Jang Bo} and Cho, {Tai Hyoung} and Park, {Jung Yul} and Kyoungmi Kim and Hur, {Junho K.} and Hur, {Junseok W.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/jor.24425",
language = "English",
journal = "Journal of Orthopaedic Research",
issn = "0736-0266",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - CCN5 Reduces Ligamentum Flavum Hypertrophy by Modulating the TGF-β Pathway

AU - Ye, Sunghyeok

AU - Kwon, Woo Keun

AU - Bae, Taegeun

AU - Kim, Sunghyun

AU - Lee, Jang Bo

AU - Cho, Tai Hyoung

AU - Park, Jung Yul

AU - Kim, Kyoungmi

AU - Hur, Junho K.

AU - Hur, Junseok W.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Ligamentum flavum hypertrophy (LFH) is the most important component of lumbar spinal canal stenosis. Although the pathophysiology of LFH has been extensively studied, no method has been proposed to prevent or treat it. Since the transforming growth factor-β (TGF-β) pathway is known to be critical in LFH pathology, we investigated whether LFH could be prevented by blocking or modulating the TGF-β mechanism. Human LF cells were used for the experiments. First, we created TGF-β receptor 1 (TGFBR1) knock out (KO) cells with CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 biotechnology and treated them with TGF-β1 to determine the effects of blocking the TGF-β pathway. Subsequently, we studied the effect of CCN5, which has recently been proposed to modulate the TGF-β pathway. To assess the predisposition toward fibrosis, α-smooth muscle actin (αSMA), fibronectin, collagen-1, collagen-3, and CCN2 were evaluated with quantitative real-time polymerase chain reaction, western blotting, and immunocytochemistry. The TGFBR1 KO LF cells were successfully constructed with high KO efficiency. In wild-type (WT) cells, treatment with TGF-β1 resulted in the overexpression of the messenger RNA (mRNA) of fibrosis-related factors. However, in KO cells, the responses to TGF-β1 stimulation were significantly lower. In addition, CCN5 and TGF-β1 co-treatment caused a notable reduction in mRNA expression levels compared with TGF-β1 stimulation only. The αSMA protein expression increased with TGF-β1 but decreased with CCN5 treatment. TGF-β1 induced LF cell transdifferentiation from fibroblasts to myofibroblasts. However, this cell transition dramatically decreased in the presence of CCN5. In conclusion, CCN5 could prevent LFH by modulating the TGF-β pathway.

AB - Ligamentum flavum hypertrophy (LFH) is the most important component of lumbar spinal canal stenosis. Although the pathophysiology of LFH has been extensively studied, no method has been proposed to prevent or treat it. Since the transforming growth factor-β (TGF-β) pathway is known to be critical in LFH pathology, we investigated whether LFH could be prevented by blocking or modulating the TGF-β mechanism. Human LF cells were used for the experiments. First, we created TGF-β receptor 1 (TGFBR1) knock out (KO) cells with CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 biotechnology and treated them with TGF-β1 to determine the effects of blocking the TGF-β pathway. Subsequently, we studied the effect of CCN5, which has recently been proposed to modulate the TGF-β pathway. To assess the predisposition toward fibrosis, α-smooth muscle actin (αSMA), fibronectin, collagen-1, collagen-3, and CCN2 were evaluated with quantitative real-time polymerase chain reaction, western blotting, and immunocytochemistry. The TGFBR1 KO LF cells were successfully constructed with high KO efficiency. In wild-type (WT) cells, treatment with TGF-β1 resulted in the overexpression of the messenger RNA (mRNA) of fibrosis-related factors. However, in KO cells, the responses to TGF-β1 stimulation were significantly lower. In addition, CCN5 and TGF-β1 co-treatment caused a notable reduction in mRNA expression levels compared with TGF-β1 stimulation only. The αSMA protein expression increased with TGF-β1 but decreased with CCN5 treatment. TGF-β1 induced LF cell transdifferentiation from fibroblasts to myofibroblasts. However, this cell transition dramatically decreased in the presence of CCN5. In conclusion, CCN5 could prevent LFH by modulating the TGF-β pathway.

KW - CCN5

KW - CRISPR

KW - ligamentum flavum

KW - myofibroblast

KW - TGF-β1

UR - http://www.scopus.com/inward/record.url?scp=85070071883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070071883&partnerID=8YFLogxK

U2 - 10.1002/jor.24425

DO - 10.1002/jor.24425

M3 - Article

C2 - 31334871

AN - SCOPUS:85070071883

JO - Journal of Orthopaedic Research

JF - Journal of Orthopaedic Research

SN - 0736-0266

ER -